Current and future treatments for malignant pheochromocytoma and sympathetic paraganglioma

Current Oncology Reports

Volumn 15, Issue 4, 2013, Pages 356-371

  Jimenez, Camilo ^a   Rohren, Eric ^a   Habra, Mouhammed Amir ^a   Rich, Thereasa ^a   Jimenez, Paola ^b   Ayala Ramirez, Montserrat ^a   Baudin, Eric ^c  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Hemato Oncologos Asociados   (Colombia)

^c INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Chemotherapy; Malignant paraganglioma; Malignant pheochromocytoma; Metaiodobenzylguanidine; Molecular targeted therapies; Surgery

Indexed keywords

(3 IODOBENZYL)GUANIDINE; ANGIOGENESIS INHIBITOR; CD135 ANTIGEN; DENOSUMAB; DOXAZOSIN; FLUORODEOXYGLUCOSE; PAZOPANIB; PHENOXYBENZAMINE; PLATELET DERIVED GROWTH FACTOR; PRAZOSIN; SUCCINATE DEHYDROGENASE; SUNITINIB; TERAZOSIN; VASCULOTROPIN;

ARTICLE; BLOOD PRESSURE; CANCER DIAGNOSIS; COMPUTER ASSISTED TOMOGRAPHY; EXTERNAL BEAM RADIOTHERAPY; GENE; GENE MUTATION; GENETIC CODE; GENETIC SCREENING; HUMAN; IMMUNOHISTOCHEMISTRY; METASTASIS POTENTIAL; MITOSIS RATE; MOLECULARLY TARGETED THERAPY; NEUROENDOCRINE TUMOR; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PARAGANGLIOMA; PHEOCHROMOCYTOMA; POSITRON EMISSION TOMOGRAPHY; SDHB GENE; SYMPTOMATOLOGY; TREATMENT DURATION; TUMOR VOLUME;

ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; HUMANS; MOLECULAR TARGETED THERAPY; PARAGANGLIOMA; PHEOCHROMOCYTOMA; RADIOPHARMACEUTICALS; SUCCINATE DEHYDROGENASE;

EID: 84880781044     PISSN: 15233790     EISSN: 15346269     Source Type: Journal    
DOI: 10.1007/s11912-013-0320-x     Document Type: Article

References (99)

1. • Ayala-Ramirez M, Feng L, Johnson MM, Ejaz S, Habra MA, Rich T, et al. Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: Primary tumor size and primary tumor location as prognostic indicators. J Clin Endocrinol Metab. 2011;96(3):717-25. To date, this is the largest published study on clinical predictors of malignancy.
2. Goldstein RE, O'Neill Jr JA, Holcomb 3rd GW, Morgan 3rd WM, Neblett 3rd WW, Oates JA, et al. Clinical experience over 48 years with pheochromocytoma. Ann Surg. 1999;229(6):755-64. discussion 764-756. (Pubitemid 30191724)
3. Adjalle R, Plouin PF, Pacak K, Lehnert H. Treatment of malignant pheochromocytoma. Horm Metab Res. 2009;41(9):687-96.
4. Patel M, Santos P, Jong I, Nandurkar D, McKay J. Malignant pheochromocytoma metastasis to the breast shown on I-123 MIBG scan. Clin Nucl Med. 2010;35(10):816-7.
5. Srinivasan R, Kini U, Babu MK, Jayaseelan E, Pradeep R. Malignant pheochromocytoma with cutaneous metastases presenting with hemolytic anemia and pyrexia of unknown origin. J Assoc Physicians India. 2002;50(5):731-3.
6. Plouin PF, Fitzgerald P, Rich T, Ayala-Ramirez M, Perrier ND, Baudin E, et al. Metastatic pheochromocytoma and paraganglioma: Focus on therapeutics. Horm Metab Res. 2012;44(5):390-9.
7. Amar L, Bertherat J, Baudin E, Ajzenberg C, Bressac-de Paillerets B, Chabre O, et al. Genetic testing in pheochromocytoma or functional paraganglioma. J Clin Oncol. 2005;23(34):8812-8. (Pubitemid 46211527)
8. Jimenez C, Cote G, Arnold A, Gagel RF. Review: Should patients with apparently sporadic pheochromocytomas or paragangliomas be screened for hereditary syndromes? J Clin Endocrinol Metab. 2006;91(8):2851-8. (Pubitemid 44271723)
9. Persu A, Lannoy N, Maiter D, Mendola A, Montigny P, Oriot P, et al. Prevalence and spectrum of SDHx mutations in pheochromocytoma and paraganglioma in patients from belgium: An update. Horm Metab Res. 2012;44(5):349-53.
10. Dahia PL, Ross KN, Wright ME, Hayashida CY, Santagata S, Barontini M, et al. A HIF1alpha regulatory loop links hypoxia and mitochondrial signals in pheochromocytomas. PLoS Genet. 2005;1(1):72-80.
11. •• Ayala-Ramirez M, Chougnet CN, Habra MA, Palmer JL, Leboulleux S, Cabanillas ME, et al. Treatment with sunitinib for patients with progressive metastatic pheochromocytomas and sympathetic paragangliomas. J Clin Endocrinol Metab. 2012;97(11):4040-50. Retrospective study that shows that sunitinib is associated with partial responses, blood pressure improvement, and decreased FDG-PET uptake, especially, in carriers of SDHB mutations.
12. Brouwers FM, Eisenhofer G, Tao JJ, Kant JA, Adams KT, Linehan WM, et al. High frequency of SDHB germline mutations in patients with malignant catecholamine-producing paragangliomas: Implications for genetic testing. J Clin Endocrinol Metab. 2006;91(11):4505-9. (Pubitemid 44833431)
13. Waguespack SG, Rich T, Grubbs E, Ying AK, Perrier ND, Ayala-Ramirez M, et al. A current review of the etiology, diagnosis, and treatment of pediatric pheochromocytoma and paraganglioma. J Clin Endocrinol Metab. 2010;95(5):2023-37.
14. Benn DE, Gimenez-Roqueplo AP, Reilly JR, Bertherat J, Burgess J, Byth K, et al. Clinical presentation and penetrance of pheochromocytoma/paraganglioma syndromes. J Clin Endocrinol Metab. 2006;91(3):827-36. (Pubitemid 43357746)
15. Burnichon N, Rohmer V, Amar L, Herman P, Leboulleux S, Darrouzet V, et al. The succinate dehydrogenase genetic testing in a large prospective series of patients with paragangliomas. J Clin Endocrinol Metab. 2009;94(8):2817-27.
16. Schiavi F, Milne RL, Anda E, Blay P, Castellano M, Opocher G, et al. Are we overestimating the penetrance of mutations in SDHB? Hum Mutat. 2010;31(6):761-2.
17. Gill AJ, Pachter NS, Chou A, Young B, Clarkson A, Tucker KM, et al. Renal tumors associated with germline SDHB mutation show distinctive morphology. Am J Surg Pathol. 2011;35(10):1578-85.
18. Pasini B, McWhinney SR, Bei T, Matyakhina L, Stergiopoulos S, Muchow M, et al. Clinical and molecular genetics of patients with the carney-stratakis syndrome and germline mutations of the genes coding for the succinate dehydrogenase subunits SDHB, SDHC, and SDHD. Eur J Hum Genet. 2008;16(1):79-88. (Pubitemid 350284184)
19. Ayala-Ramirez M, Callender GG, Kupferman ME, Rich TA, Chuang HH, Trent J, et al. Paraganglioma syndrome type 1 in a patient with carney-stratakis syndrome. Nat Rev Endocrinol. 2010;6(2):110-5.
20. Selak MA, Armour SM, MacKenzie ED, Boulahbel H, Watson DG, Mansfield KD, et al. Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell. 2005;7(1):77-85. (Pubitemid 40126384)
21. Pollard PJ, Briere JJ, Alam NA, Barwell J, Barclay E, Wortham NC, et al. Accumulation of krebs cycle intermediates and over-expression of HIF1alpha in tumours which result from germline FH and SDH mutations. Hum Mol Genet. 2005;14(15):2231-9. (Pubitemid 41418022)
22. Gottlieb E, Tomlinson IP. Mitochondrial tumour suppressors: A genetic and biochemical update. Nat Rev Cancer. 2005;5(11):857-66. (Pubitemid 41746030)
23. Loriot C, Burnichon N, Gadessaud N, Vescovo L, Amar L, Libe R, et al. Epithelial to mesenchymal transition is activated in metastatic pheochromocytomas and paragangliomas caused by SDHB gene mutations. J Clin Endocrinol Metab. 2012;97(6):E954-62.
24. Cascon A, Montero-Conde C, Ruiz-Llorente S, Mercadillo F, Leton R, Rodriguez-Antona C, et al. Gross SDHB deletions in patients with paraganglioma detected by multiplex PCR: A possible hot spot? Genes Chromosomes Cancer. 2006;45(3):213-9. (Pubitemid 43238472)
25. van Nederveen FH, Gaal J, Favier J, Korpershoek E, Oldenburg RA, de Bruyn EM, et al. An immunohistochemical procedure to detect patients with paraganglioma and phaeochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: A retrospective and prospective analysis. Lancet Oncol. 2009;10(8):764-71.
26. Burnichon N, Cascon A, Schiavi F, Morales NP, Comino-Mendez I, Abermil N, et al. MAX mutations cause hereditary and sporadic pheochromocytoma and paraganglioma. Clin Cancer Res. 2012;18(10):2828-37.
27. Comino-Mendez I, Gracia-Aznarez FJ, Schiavi F, Landa I, Leandro-Garcia LJ, Leton R, et al. Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma. Nat Genet. 2011;43(7):663-7.
28. Amar L, Fassnacht M, Gimenez-Roqueplo AP, Januszewicz A, Prejbisz A, Timmers H, et al. Long-term postoperative follow-up in patients with apparently benign pheochromocytoma and paraganglioma. Horm Metab Res. 2012;44(5):385-9.
29. Park J, Song C, Park M, Yoo S, Park SJ, Hong S, et al. Predictive characteristics of malignant pheochromocytoma. Korean J Urol. 2011;52(4):241-6.
30. John H, Ziegler WH, Hauri D, Jaeger P. Pheochromocytomas: Can malignant potential be predicted? Urology. 1999;53(4):679-83. (Pubitemid 29163029)
31. Feng F, Zhu Y, Wang X, Wu Y, Zhou W, Jin X, et al. Predictive factors for malignant pheochromocytoma: analysis of 136 patients. J Urol. 2011;185(5):1583-90.
32. Amar L, Baudin E, Burnichon N, Peyrard S, Silvera S, Bertherat J, et al. Succinate dehydrogenase B gene mutations predict survival in patients with malignant pheochromocytomas or paragangliomas. J Clin Endocrinol Metab. 2007;92(10):3822-8. (Pubitemid 47607629)
33. Gimenez-Roqueplo AP, Favier J, Rustin P, Rieubland C, Kerlan V, Plouin PF, et al. Functional consequences of a SDHB gene mutation in an apparently sporadic pheochromocytoma. J Clin Endocrinol Metab. 2002;87(10):4771-4. (Pubitemid 35247074)
34. Zelinka T, Petrak O, Turkova H, Holaj R, Strauch B, Krsek M, et al. High incidence of cardiovascular complications in pheochromocytoma. Horm Metab Res. 2012;44(5):379-84.
35. Mason LD, Prentice WM, Whitelaw BC. An unusual case of severe constipation due to metastatic pheochromocytoma. J Pain Symptom Manage. 2009;37(6):e5-7.
36. Timmers HJ, Brouwers FM, Hermus AR, Sweep FC, Verhofstad AA, Verbeek AL, et al. Metastases but not cardiovascular mortality reduces life expectancy following surgical resection of apparently benign pheochromocytoma. Endocr Relat Cancer. 2008;15(4):1127-33.
37. • Ayala-Ramirez M, Palmer JL, Hoffman MC, de la Cruz M, Moon BS, Waguespack SG, Habra MA, Jimenez C: Bone Metastases and Skeletal-Related Events in Patients with Malignant Pheochromocytoma and Sympathetic Paraganglioma. J Clin Endocrinol Metab 2013. Systemic therapy and antiresortives may prevent skeletal related events in patients with malignant PHs and SPGs.
38. Zelinka T, Timmers HJ, Kozupa A, Chen CC, Carrasquillo JA, Reynolds JC, et al. Role of positron emission tomography and bone scintigraphy in the evaluation of bone involvement in metastatic pheochromocytoma and paraganglioma: Specific implications for succinate dehydrogenase enzyme subunit B gene mutations. Endocr Relat Cancer. 2008;15(1):311-23. (Pubitemid 351449749)
39. Timmers HJ, Kozupa A, Chen CC, Carrasquillo JA, Ling A, Eisenhofer G, et al. Superiority of fluorodeoxyglucose positron emission tomography to other functional imaging techniques in the evaluation of metastatic SDHB-associated pheochromocytoma and paraganglioma. J Clin Oncol. 2007;25(16):2262-9. (Pubitemid 46954653)
40. Amar L, Servais A, Gimenez-Roqueplo AP, Zinzindohoue F, Chatellier G, Plouin PF. Year of diagnosis, features at presentation, and risk of recurrence in patients with pheochromocytoma or secreting paraganglioma. J Clin Endocrinol Metab. 2005;90(4):2110-6. (Pubitemid 40586247)
41. Eisenhofer G, Siegert G, Kotzerke J, Bornstein SR, Pacak K. Current progress and future challenges in the biochemical diagnosis and treatment of pheochromocytomas and paragangliomas. Horm Metab Res. 2008;40(5):329-37. (Pubitemid 351859444)
42. Plouin PF. Use of plasma chromogranin A and urine fractionated metanephrines to diagnose pheochromocytoma? Nat Clin Pract Endocrinol Metab. 2008;4(6):314-5.
43. Rao F, Keiser HR, O'Connor DT. Malignant pheochromocytoma. Chromaffin granule transmitters and response to treatment. Hypertension. 2000;36(6):1045-52.
44. Timmers HJ, Chen CC, Carrasquillo JA, Whatley M, Ling A, Havekes B, et al. Comparison of 18F-fluoro-L-DOPA, 18F-fluoro-deoxyglucose, and 18F-fluorodopamine PET and 123I-MIBG scintigraphy in the localization of pheochromocytoma and paraganglioma. J Clin Endocrinol Metab. 2009;94(12):4757-67.
45. Chrisoulidou A, Kaltsas G, Ilias I, Grossman AB. The diagnosis and management of malignant phaeochromocytoma and paraganglioma. Endocr Relat Cancer. 2007;14(3):569-85. (Pubitemid 350074048)
46. Mundschenk J, Lehnert H. Malignant pheochromocytoma. Exp Clin Endocrinol Diabetes. 1998;106(5):373-6. (Pubitemid 28491201)
47. Kopf D, Goretzki PE, Lehnert H. Clinical management of malignant adrenal tumors. J Cancer Res Clin Oncol. 2001;127(3):143-55. (Pubitemid 32449065)
48. Nonaka K, Makuuchi H, Naruse Y, Kobayashi T, Goto M. Surgical excision of malignant pheochromocytoma in the left atrium. Jpn J Thorac Cardiovasc Surg. 2000;48(2):126-8.
49. Mannelli M. Management and treatment of pheochromocytomas and paragangliomas. Ann N Y Acad Sci. 2006;1073:405-16. (Pubitemid 44912035)
50. Eisenhofer G, Rivers G, Rosas AL, Quezado Z, Manger WM, Pacak K. Adverse drug reactions in patients with phaeochromocytoma: Incidence, prevention and management. Drug Saf. 2007;30(11):1031-62. (Pubitemid 350036603)
51. Buhl T, Mortensen J, Kjaer A. I-123 MIBG imaging and intraoperative localization of metastatic pheochromocytoma: A case report. Clin Nucl Med. 2002;27(3):183-5. (Pubitemid 34195230)
52. Whalen RK, Althausen AF, Daniels GH. Extra-adrenal pheochromocytoma. J Urol. 1992;147(1):1-10.
53. McBride JF, Atwell TD, Charboneau WJ, Young Jr WF, Wass TC, Callstrom MR. Minimally invasive treatment of metastatic pheochromocytoma and paraganglioma: Efficacy and safety of radiofrequency ablation and cryoablation therapy. J Vasc Interv Radiol. 2011;22(9):1263-70.
54. Immergut MA, Boldus R, Kollin CP, Rohlf P. The management of ectopic pheochromocytoma producing ureteral obstruction. J Urol. 1970;104(2):337-41.
55. Morales JO, Beierwaltes WH, Counsell RE, Meier DH. The concentration of radioactivity from labeled epinephrine and its precursors in the dog adrenal medulla. J Nucl Med. 1967;8(11):800-9.
56. Beierwaltes WH, Wieland DM, Yu T, Swanson DP, Mosley ST. Adrenal imaging agents: Rationale, synthesis, formulation and, metabolism. Semin Nucl Med. 1978;8(1):5-21. (Pubitemid 8282217)
57. Lieberman LM, Beierwaltes WH, Varma VM, Weinhold P, Ling R. Labeled dopamine concentration in human adrenal medulla and in neuroblastoma. J Nucl Med. 1969;10(2):93-7.
58. Anderson BG, Beierwaltes WH, Harrison TS, Ansari AN, Buswink AA, Ice RD. Labeled dopamine concentration in pheochromocytomas. J Nucl Med. 1973;14(11):781-4.
59. Wieland DM, Swanson DP, Brown LE, Beierwaltes WH. Imaging the adrenal medulla with an I-131-labeled antiadrenergic agent. J Nucl Med. 1979;20(2):155-8. (Pubitemid 9129566)
60. Wieland DM, Wu J, Brown LE, Mangner TJ, Swanson DP, Beierwaltes WH. Radiolabeled adrenergi neuron-blocking agents: Adrenomedullary imaging with [131I]iodobenzylguanidine. J Nucl Med. 1980;21(4):349-53. (Pubitemid 10100562)
61. Sisson JC, Shapiro B, Beierwaltes WH, Glowniak JV, Nakajo M, Mangner TJ, et al. Radiopharmaceutical treatment of malignant pheochromocytoma. J Nucl Med. 1984;25(2):197-206. (Pubitemid 14187477)
62. Loh KC, Fitzgerald PA, Matthay KK, Yeo PP, Price DC. The treatment of malignant pheochromocytoma with iodine-131 metaiodobenzylguanidine (131I-MIBG): a comprehensive review of 116 reported patients. J Endocrinol Invest. 1997;20(11):648-58. (Pubitemid 28056835)
63. • Gonias S, Goldsby R, Matthay KK, Hawkins R, Price D, Huberty J, et al. Phase II study of high-dose [131I]metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma. J Clin Oncol. 2009;27(25):4162-8. To date, this is the only published phase 2 clinical trial against metastatic PH and SPG; this study describes the clinical benefits derived from MIBG therapy.
64. Gulenchyn KY, Yao X, Asa SL, Singh S, Law C. Radionuclide therapy in neuroendocrine tumours: A systematic review. Clin Oncol (R Coll Radiol). 2012;24(4):294-308.
65. Madsen MT, Bushnell DL, Juweid ME, Menda Y, O'Dorisio MS, O'Dorisio T, et al. Potential increased tumor-dose delivery with combined 131I-MIBG and 90Y-DOTATOC treatment in neuroendocrine tumors: A theoretic model. J Nucl Med. 2006;47(4):660-7. (Pubitemid 46768468)
66. Yanik GA, Levine JE, Matthay KK, Sisson JC, Shulkin BL, Shapiro B, et al. Pilot study of iodine-131-metaiodobenzylguanidine in combination with myeloablative chemotherapy and autologous stem-cell support for the treatment of neuroblastoma. J Clin Oncol. 2002;20(8):2142-9. (Pubitemid 34408806)
67. Fueger BJ, Hamilton G, Raderer M, Pangerl T, Traub T, Angelberger P, et al. Effects of chemotherapeutic agents on expression of somatostatin receptors in pancreatic tumor cells. J Nucl Med. 2001;42(12):1856-62. (Pubitemid 34016357)
68. Keiser HR, Goldstein DS, Wade JL, Douglas FL, Averbuch SD. Treatment of malignant pheochromocytoma with combination chemotherapy. Hypertension. 1985;7(3 Pt 2):I18-24. (Pubitemid 15005755)
69. Averbuch SD, Steakley CS, Young RC, Gelmann EP, Goldstein DS, Stull R, et al. Malignant pheochromocytoma: Effective treatment with a combination of cyclophosphamide, vincristine, and dacarbazine. Ann Intern Med. 1988;109(4):267-73.
70. Huang H, Abraham J, Hung E, Averbuch S, Merino M, Steinberg SM, et al. Treatment of malignant pheochromocytoma/paraganglioma with cyclophosphamide, vincristine, and dacarbazine: Recommendation from a 22-year follow-up of 18 patients. Cancer. 2008;113(8):2020-8.
71. Patel SR, Winchester DJ, Benjamin RS. A 15-year experience with chemotherapy of patients with paraganglioma. Cancer. 1995;76(8):1476-80.
72. Tanabe A, Naruse M, Nomura K, Tsuiki M, Tsumagari A, Ichihara A. Combination chemotherapy with cyclophosphamide, vincristine, and dacarbazine in patients with malignant pheochromocytoma and paraganglioma. Horm Cancer. 2013;4(2):103-10.
73. • Ayala-Ramirez M, Feng L, Habra MA, Rich T, Dickson PV, Perrier N, et al. Clinical benefits of systemic chemotherapy for patients with metastatic pheochromocytomas or sympathetic extra-adrenal paragangliomas: Insights from the largest single-institutional experience. Cancer. 2012;118(11):2804-12. First study that shows that a positive response to chemotherapy is associated with a longer overall survival.
74. Srimuninnimit V, Wampler GL. Case report of metastatic familial pheochromocytoma treated with cisplatin and 5-fluorouracil. Cancer Chemother Pharmacol. 1991;28(3):217-9.
75. Grogan RH, Mitmaker EJ, Duh QY. Changing paradigms in the treatment of malignant pheochromocytoma. Cancer Control. 2011;18(2):104-12.
76. Scharf Y, Nahir AM, Better OS, Koten A, Arieh YB, Gellei B. Prolonged survival in malignant pheochromocytoma of the organ of Zuckerkandl with pharmacological treatment. Cancer. 1973;31(3):746-50.
77. Kulke MH, Stuart K, Enzinger PC, Ryan DP, Clark JW, Muzikansky A, et al. Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol. 2006;24(3):401-6. (Pubitemid 46630459)
78. Feldman JM. Treatment of metastatic pheochromocytoma with streptozocin. Arch Intern Med. 1983;143(9):1799-800. (Pubitemid 13007166)
79. Scholz T, Eisenhofer G, Pacak K, Dralle H, Lehnert H. Clinical review: Current treatment of malignant pheochromocytoma. J Clin Endocrinol Metab. 2007;92(4):1217-25. (Pubitemid 46556388)
80. Gimenez-Roqueplo AP, Favier J, Rustin P, Mourad JJ, Plouin PF, Corvol P, et al. The R22X mutation of the SDHD gene in hereditary paraganglioma abolishes the enzymatic activity of complex II in the mitochondrial respiratory chain and activates the hypoxia pathway. Am J Hum Genet. 2001;69(6):1186-97. (Pubitemid 33124200)
81. Favier J, Briere JJ, Burnichon N, Riviere J, Vescovo L, Benit P, et al. The Warburg effect is genetically determined in inherited pheochromocytomas. PLoS One. 2009;4(9):e7094.
82. Favier J, Plouin PF, Corvol P, Gasc JM. Angiogenesis and vascular architecture in pheochromocytomas: Distinctive traits in malignant tumors. Am J Pathol. 2002;161(4):1235-46.
83. Salmenkivi K, Heikkila P, Liu J, Haglund C, Arola J. VEGF in 105 pheochromocytomas: enhanced expression correlates with malignant outcome. APMIS. 2003;111(4):458-64. (Pubitemid 36735003)
84. Takekoshi K, Isobe K, Yashiro T, Hara H, Ishii K, Kawakami Y, et al. Expression of vascular endothelial growth factor (VEGF) and its cognate receptors in human pheochromocytomas. Life Sci. 2004;74(7):863-71. (Pubitemid 37501135)
85. Brieger J, Bedavanija A, Gosepath J, Maurer J, Mann WJ. Vascular endothelial growth factor expression, vascularization and proliferation in paragangliomas. ORL J Otorhinolaryngol Relat Spec. 2005;67(2):119-24. (Pubitemid 40868748)
86. Burnichon N, Vescovo L, Amar L, Libe R, de Reynies A, Venisse A, et al. Integrative genomic analysis reveals somatic mutations in pheochromocytoma and paraganglioma. Hum Mol Genet. 2011;20(20):3974-85.
87. Lopez-Jimenez E, Gomez-Lopez G, Leandro-Garcia LJ, Munoz I, Schiavi F, Montero-Conde C, et al. Research resource: Transcriptional profiling reveals different pseudohypoxic signatures in SDHB and VHL-related pheochromocytomas. Mol Endocrinol. 2010;24(12):2382-91.
88. Joshua AM, Ezzat S, Asa SL, Evans A, Broom R, Freeman M, et al. Rationale and evidence for sunitinib in the treatment of malignant paraganglioma/ pheochromocytoma. J Clin Endocrinol Metab. 2009;94(1):5-9.
89. Jimenez C, Cabanillas ME, Santarpia L, Jonasch E, Kyle KL, Lano EA, et al. Use of the tyrosine kinase inhibitor sunitinib in a patient with von Hippel-Lindau disease: targeting angiogenic factors in pheochromocytoma and other von Hippel-Lindau disease-related tumors. J Clin Endocrinol Metab. 2009;94(2):386-91.
90. Park KS, Lee JL, Ahn H, Koh JM, Park I, Choi JS, et al. Sunitinib, a novel therapy for anthracycline- and cisplatin-refractory malignant pheochromocytoma. Jpn J Clin Oncol. 2009;39(5):327-31.
91. Herrmann E, Bierer S, Wulfing C. Update on systemic therapies of metastatic renal cell carcinoma. World J Urol. 2010;28(3):303-9.
92. • Burnichon N, Buffet A, Parfait B, Letouze E, Laurendeau I, Loriot C, et al. Somatic NF1 inactivation is a frequent event in sporadic pheochromocytoma. Hum Mol Genet. 2012;21(26):5397-405. Somatic NF1 mutations are present in some sporadic malignant PHs and SPGs; mTOR and MEK inhibitors might be explored in clinical trials against metastatic disease.
93. Dancey JE. Therapeutic targets: MTOR and related pathways. Cancer Biol Ther. 2006;5(9):1065-73. (Pubitemid 44773684)
94. Druce MR, Kaltsas GA, Fraenkel M, Gross DJ, Grossman AB. Novel and evolving therapies in the treatment of malignant phaeochromocytoma: Experience with the mTOR inhibitor everolimus (RAD001). Horm Metab Res. 2009;41(9):697-702.
95. Oh DY, Kim TW, Park YS, Shin SJ, Shin SH, Song EK, et al. Phase 2 study of everolimus monotherapy in patients with nonfunctioning neuroendocrine tumors or pheochromocytomas/paragangliomas. Cancer. 2012;118(24):6162-70.
96. Ikezoe T, Nishioka C, Tasaka T, Yang Y, Komatsu N, Togitani K, et al. The antitumor effects of sunitinib (formerly SU11248) against a variety of human hematologic malignancies: enhancement of growth inhibition via inhibition of mammalian target of rapamycin signaling. Mol Cancer Ther. 2006;5(10):2522-30. (Pubitemid 44650916)
97. Favier J, Igaz P, Burnichon N, Amar L, Libe R, Badoual C, et al. Rationale for anti-angiogenic therapy in pheochromocytoma and paraganglioma. Endocr Pathol. 2012;23(1):34-42.
98. Molina AM, Feldman DR, Voss MH, Ginsberg MS, Baum MS, Brocks DR, et al. Phase 1 trial of everolimus plus sunitinib in patients with metastatic renal cell carcinoma. Cancer. 2012;118(7):1868-76.
99. Santarpia L, Habra MA, Jimenez C. Malignant pheochromocytomas and paragangliomas: Molecular signaling pathways and emerging therapies. Horm Metab Res. 2009;41(9):680-6.